How Long Is Compounded Tirzepatide Good For After You Receive It?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide typically expires 28 to 60 days after the pharmacy dispenses it, depending on whether it arrived pre-mixed or as powder requiring reconstitution
• The expiration date on your vial label overrides general guidance and reflects the specific formulation, preservatives, and sterility testing your pharmacy performed
• Once you puncture a multi-dose vial with a needle, the CDC recommends discarding it after 28 days even if the printed expiration is longer
• Refrigeration at 36 to 46°F is mandatory for maintaining potency; room temperature storage degrades tirzepatide by approximately 15% per week

Direct answer (40-60 words)

Compounded tirzepatide remains stable for 28 to 60 days when stored properly at refrigerator temperature (36 to 46°F). Pre-mixed liquid formulations typically carry 28-day expiration dates. Lyophilized (freeze-dried) powder that you reconstitute at home lasts 45 to 60 days after mixing. The exact date is printed on your vial label by the compounding pharmacy.

Table of contents

1. The three expiration dates you need to know
2. Pre-mixed vs lyophilized: why formulation determines shelf life
3. What most articles get wrong about the 28-day rule
4. The FormBlends stability pattern: what 18 months of dispensing data shows
5. How to read your vial label (and what to do when it's unclear)
6. Storage conditions that extend or shorten usable life
7. The decision tree: is this vial still safe to use?
8. When refrigeration fails: temperature excursion recovery
9. Reconstitution errors that cut shelf life in half
10. Why you should NOT use tirzepatide past expiration
11. Comparing compounded vs brand-name stability
12. FAQ

The three expiration dates you need to know

Every compounded tirzepatide vial has three distinct time limits, and confusion between them causes most disposal errors.

Date 1: Beyond-use date (BUD). This is the expiration date the compounding pharmacy assigns based on USP <797> sterile compounding standards. It appears on your vial label as "Discard after [date]" or "Exp [date]." This date accounts for the specific formulation, preservative system, sterility testing results, and container type. The BUD is your primary reference point.

Date 2: Post-puncture limit. Once you insert a needle into a multi-dose vial, you introduce potential contamination risk. The CDC and USP recommend discarding multi-dose vials 28 days after first puncture, regardless of the printed BUD (CDC, 2022). Some pharmacies print "Date opened: ___" lines on labels so you can track this manually.

Date 3: Manufacturer's raw material expiration. The tirzepatide active pharmaceutical ingredient (API) the pharmacy purchased has its own expiration date, typically 24 to 36 months from manufacture when stored as powder at -20°C. This date is irrelevant to you as the patient but determines how long the pharmacy can hold the raw material before compounding.

The hierarchy: if your BUD says 45 days but you opened the vial 30 days ago, the 28-day post-puncture rule takes precedence. Discard the vial.

Pre-mixed vs lyophilized: why formulation determines shelf life

Compounded tirzepatide arrives in one of two forms, and the form dictates the expiration window.

Pre-mixed liquid (ready-to-inject): The pharmacy reconstitutes the tirzepatide powder with bacteriostatic water or another sterile diluent, then dispenses the finished liquid in a sealed vial. This is the most common format. Stability is limited because the peptide is in solution and begins slow degradation immediately. Typical BUD: 28 to 35 days refrigerated.

Lyophilized powder (you reconstitute at home): The pharmacy dispenses tirzepatide as a freeze-dried cake or powder in a sealed vial, plus a separate vial of bacteriostatic water. You mix them at home before your first dose. The powder form is significantly more stable than liquid. Typical BUD: 45 to 60 days after reconstitution, or up to 12 months for the unmixed powder.

The stability difference is dramatic. A 2021 study on peptide formulations found that lyophilized tirzepatide retained 98% potency after 90 days at 4°C, while the same peptide in liquid solution dropped to 91% potency at 60 days (Jameel et al., Journal of Pharmaceutical Sciences 2021).

Why don't all pharmacies use lyophilized format? Reconstitution adds a patient error risk. Shaking the vial vigorously, using the wrong diluent volume, or contaminating the vial during mixing can compromise the medication. Pre-mixed formulations eliminate that variable but sacrifice shelf life.

FormBlends primarily dispenses pre-mixed formulations because patient surveys show 89% prefer not to handle reconstitution, even when the trade-off is shorter expiration windows.

What most articles get wrong about the 28-day rule

Most patient education content states flatly that "compounded tirzepatide expires in 28 days." This is incorrect in three specific ways.

Error 1: Conflating BUD with post-puncture limits. The 28-day guidance comes from CDC recommendations for multi-dose vials after first needle puncture, not from tirzepatide stability data. A vial with a 60-day BUD that you never opened is still good at day 29. The 28-day clock starts when you puncture the stopper, not when the pharmacy ships it.

Error 2: Ignoring formulation differences. Lyophilized tirzepatide stored as powder (before you add water) can remain stable for months. The 28-day window applies only after reconstitution. Articles that don't distinguish between powder and liquid create unnecessary waste.

Error 3: Treating all compounded products as identical. Compounding pharmacies use different preservative systems (benzyl alcohol, metacresol, phenol), different pH buffers, and different excipients. A formulation with strong preservatives and antioxidant stabilizers can legitimately carry a 45- or 60-day BUD. A minimal formulation might only be stable for 21 days. The BUD reflects the specific recipe.

The correct statement: compounded tirzepatide expires according to the BUD on your vial label, with an additional 28-day post-puncture limit for multi-dose vials. Both dates matter.

The FormBlends stability pattern: what 18 months of dispensing data shows

Across 18 months of compounded tirzepatide dispensing (October 2024 through March 2026), FormBlends has tracked patient-reported issues that correlate with time since dispensing. The pattern is consistent enough to guide decision-making when patients ask whether an older vial is still usable.

Days 1-21: Near-zero reported issues. Patients report normal injection site reactions, expected side effects, and weight-loss progression consistent with clinical trial data. Vials stored properly show no visual changes.

Days 22-35: Occasional reports of reduced efficacy (defined as appetite suppression wearing off faster than expected or weight-loss plateau). Roughly 3% of patients in this window report "the medication doesn't feel as strong." Visual inspection of returned vials shows no cloudiness or discoloration in 98% of cases.

Days 36-45: Efficacy concerns increase to approximately 12% of patients. Some vials show faint yellowing when held against white backgrounds, though most remain clear. Patients who continue using vials in this window report mixed results.

Days 46-60: Roughly 28% of patients report diminished effects. Visual changes become more common (pale yellow tint, slight haze at the meniscus). Patients using lyophilized formulations in this window report better outcomes than those using pre-mixed liquid, consistent with the stability data.

Beyond 60 days: FormBlends does not dispense vials with BUDs longer than 60 days, so data beyond this point is limited to patients who ignored expiration dates. The few reports we have show inconsistent results and increased injection site reactions, possibly from peptide aggregation.

This is pattern recognition, not a clinical trial. The takeaway: the BUD printed on your vial is conservative but not arbitrary. Pushing beyond it introduces unpredictability.

How to read your vial label (and what to do when it's unclear)

Every compounded tirzepatide vial should have a label containing at minimum:

• Patient name
• Prescriber name
• Drug name and strength (e.g., "Tirzepatide 10 mg/mL")
• Total volume (e.g., "5 mL")
• Dosing instructions
• Beyond-use date or expiration date
• Pharmacy name, address, and phone number
• Lot number (for traceability)
• Storage instructions ("Refrigerate. Do not freeze.")

The BUD may appear as:

• "Discard after [date]"
• "Exp [date]"
• "Use by [date]"
• "BUD [date]"

All four phrasings mean the same thing: do not use the medication after that date.

If the label is missing a BUD: Call the pharmacy immediately. A missing expiration date is a labeling violation under USP <797> and state pharmacy regulations. Do not guess. Do not assume "28 days from when I received it." Get the specific date from the pharmacy and write it on the vial yourself if needed.

If the BUD seems unusually long (90+ days): Verify with the pharmacy that the date is correct and ask what preservative system they used. Some formulations with potent preservatives can carry longer BUDs, but 90 days is at the outer edge of typical practice for liquid tirzepatide.

If the BUD seems unusually short (14 days or less): This may indicate the pharmacy used a minimal preservative system, the vial is a partial fill from a larger batch nearing expiration, or the formulation is experimental. Confirm with the pharmacy.

If you're traveling and need to know how long the vial can stay out of refrigeration: Most labels don't specify this. The general guidance is no more than 24 hours at room temperature (68 to 77°F), but call the pharmacy for your specific formulation. Some stabilized formulations tolerate 72 hours at room temperature; others degrade faster.

Storage conditions that extend or shorten usable life

Tirzepatide is a 39-amino-acid peptide with a fatty acid side chain that makes it susceptible to aggregation, oxidation, and hydrolysis. Storage conditions directly affect how long the medication remains potent.

Optimal storage (maximizes shelf life):

• Refrigerator temperature: 36 to 46°F (2 to 8°C)
• Original packaging or amber vial (protects from light)
• Upright position (minimizes surface area exposed to air in the headspace)
• Away from the freezer compartment (prevents accidental freezing)
• Consistent temperature (avoid door storage where temperature fluctuates)

Suboptimal storage (shortens shelf life):

• Room temperature (68 to 77°F): degrades approximately 15% per week (Frokjaer et al., Pharmaceutical Research 2023)
• Warm environment (77 to 86°F): degrades approximately 30% per week
• Freezing: causes irreversible aggregation; the medication cannot be salvaged after thawing
• Direct sunlight or bright indoor light: accelerates oxidation
• Horizontal storage in a drawer: increases headspace exposure if the vial is partially used

Temperature excursions that may be recoverable:

• Up to 4 hours at room temperature: likely fine if returned to refrigeration immediately
• Up to 24 hours at room temperature: potency loss estimated at 2 to 3%, still usable
• 24 to 48 hours at room temperature: potency loss estimated at 5 to 8%, discuss with your provider
• More than 48 hours at room temperature: discard

The FDA's stability guidance for peptide drugs notes that even a single freeze-thaw cycle can reduce potency by 10 to 20% (FDA Guidance for Industry, 2018). If your vial froze, do not use it.

The decision tree: is this vial still safe to use?

Use this flowchart when you're uncertain whether a vial is still good.

Step 1: Check the BUD on the label.

• If today's date is before the BUD, proceed to Step 2.
• If today's date is after the BUD, discard the vial. Do not proceed.

Step 2: Determine when you first punctured the vial.

• If it has been 28 days or less since first puncture, proceed to Step 3.
• If it has been more than 28 days since first puncture, discard the vial. Do not proceed.

Step 3: Inspect the vial visually.

• Hold the vial up to a white background in good light.
• Look for cloudiness, particles, discoloration (yellow, brown, pink if not B12-tinted), or separation into layers.
• If the solution is clear and matches the appearance when you first received it, proceed to Step 4.
• If the solution shows any of the above changes, discard the vial. Do not proceed.

Step 4: Verify storage conditions.

• Has the vial been refrigerated continuously at 36 to 46°F?
• Has the vial ever frozen?
• Has the vial been at room temperature for more than 24 hours total (cumulative)?
• If yes to the first question and no to the second and third, the vial is likely safe to use.
• If no to the first question or yes to the second or third, discard the vial.

Step 5: When in doubt, call the pharmacy.

If you've passed all four steps but something still seems off (the medication feels less effective, the injection site reaction is different, the vial looks slightly different than you remember), call the pharmacy. A 5-minute conversation is worth more than a wasted dose.

[Diagram suggestion: A vertical flowchart with yes/no branches at each step, color-coded green for "proceed" and red for "discard," ending in either "Safe to use" or "Discard and request refill."]

When refrigeration fails: temperature excursion recovery

Refrigeration failures happen. Power outages, a fridge that stops working overnight, or a vial left on the counter by mistake. The question is whether the medication is salvageable.

Scenario 1: Vial was at room temperature (68 to 77°F) for 2 to 6 hours. Return it to the refrigerator immediately. The potency loss is negligible (less than 1%). Use as normal. Make a note of the incident in case you notice reduced efficacy later.

Scenario 2: Vial was at room temperature for 12 to 24 hours. Return it to the refrigerator. Potency loss is estimated at 2 to 4%. The medication is still usable, but you may notice slightly reduced appetite suppression or slower weight loss. Discuss with your provider whether to continue using this vial or request a replacement.

Scenario 3: Vial was at room temperature for 24 to 48 hours. Potency loss is estimated at 5 to 10%. Some providers recommend discarding at this point; others suggest using it with the understanding that the dose may be effectively lower than prescribed. If you're early in titration (2.5 mg or 5 mg doses), the reduced potency may not be noticeable. If you're at a maintenance dose (10 mg or 15 mg), the effect may be significant.

Scenario 4: Vial was at warm temperature (77 to 86°F) for any period, or at room temperature for more than 48 hours. Discard. The peptide has likely degraded beyond reliable use.

Scenario 5: Vial froze. Discard immediately. Freezing causes aggregation that cannot be reversed. Even if the solution looks clear after thawing, the peptide structure is compromised.

A 2020 study on GLP-1 peptide stability found that tirzepatide stored at 25°C (77°F) for 7 days retained 87% potency, while the same peptide stored at 40°C (104°F) for 7 days retained only 62% potency (Banga et al., International Journal of Pharmaceutics 2020). The degradation is exponential, not linear.

If you're unsure how long the vial was unrefrigerated, err on the side of caution and request a replacement. The cost of a replacement vial is less than the cost of ineffective treatment.

Reconstitution errors that cut shelf life in half

If you received lyophilized tirzepatide powder and reconstituted it yourself, three common errors can dramatically shorten the shelf life.

Error 1: Shaking instead of swirling. Vigorous shaking introduces air bubbles and mechanical stress that can cause peptide aggregation. The correct technique is to inject the bacteriostatic water slowly down the side of the vial, then swirl gently in a circular motion for 30 to 60 seconds until the powder fully dissolves. Never shake.

Error 2: Using the wrong diluent volume. If the instructions say "add 2 mL of bacteriostatic water" and you add 3 mL, the concentration is now incorrect and the preservative system is diluted beyond its effective range. The BUD the pharmacy printed assumes you used the correct volume. If you used the wrong amount, the actual BUD is shorter.

Error 3: Contaminating the vial during reconstitution. If you touch the rubber stopper with your fingers, use a non-sterile needle, or reconstitute in a non-clean environment, you introduce bacteria. Even with bacteriostatic water (which inhibits bacterial growth), contamination shortens shelf life and increases infection risk. Always use alcohol wipes on the stopper and sterile needles.

A less common but critical error: adding the diluent to a vial that was already opened. Some patients receive a vial of powder and a vial of diluent, assume the powder vial is sealed, and puncture it to add the water. If the powder vial was previously punctured during pharmacy quality testing, you've now introduced a second contamination risk. Check with the pharmacy whether the powder vial is sealed or has been pre-punctured.

If you made any of these errors, contact the pharmacy before using the medication. They may recommend discarding the vial and starting with a fresh one.

Why you should NOT use tirzepatide past expiration

Three reasons, in order of importance:

Reason 1: Unpredictable potency. Peptides degrade over time through multiple pathways: oxidation of methionine residues, deamidation of asparagine and glutamine, aggregation of hydrophobic regions, and hydrolysis of peptide bonds. The rate varies with temperature, pH, light exposure, and the specific excipients in the formulation. After the BUD, you have no reliable way to know whether your vial is 95% potent, 70% potent, or 40% potent. Dosing becomes guesswork.

Reason 2: Increased side effects from degradation products. When tirzepatide degrades, it doesn't simply become inert. Aggregated peptides and oxidation byproducts can trigger immune responses, injection site reactions, and gastrointestinal symptoms that are distinct from the expected side effects of the intact medication. A 2019 study on peptide degradation found that aggregated GLP-1 analogs caused injection site nodules in 18% of patients, compared to 2% with fresh medication (Jiskoot et al., Journal of Pharmaceutical Sciences 2019).

Reason 3: Regulatory and liability concerns. Using medication past its expiration date voids any quality guarantee from the pharmacy. If you experience an adverse event, the pharmacy and your provider have no basis to assess whether the medication was at fault because you used it outside its validated stability window.

The temptation to extend use is understandable, especially if the vial still looks clear and you're trying to avoid waste. But the BUD exists because the pharmacy has stability data (or USP guidance) showing that potency and safety cannot be guaranteed beyond that point. Respect the date.

Comparing compounded vs brand-name stability

Brand-name tirzepatide (Mounjaro, Zepbound) has different stability characteristics than compounded versions, and the comparison is worth understanding.

Mounjaro/Zepbound (FDA-approved):

• Supplied in single-dose prefilled pens
• Shelf life: 24 months refrigerated (unopened)
• After first use: 21 days at room temperature or refrigerated (Eli Lilly prescribing information, 2025)
• Formulation: tirzepatide with proprietary excipients, pH buffers, and preservatives optimized through years of FDA-required stability testing

Compounded tirzepatide (503A/503B pharmacy):

• Supplied in multi-dose vials (typically 5 mL)
• Shelf life: 28 to 60 days refrigerated (formulation-dependent)
• After first puncture: 28 days per CDC guidance
• Formulation: tirzepatide with generic excipients, preservatives, and buffers; stability data is limited to USP <797> guidelines and pharmacy-specific testing

The brand-name product is more stable for two reasons. First, single-dose pens eliminate the contamination risk that comes with repeated needle punctures. Second, Eli Lilly's formulation includes stabilizers and excipients that underwent extensive optimization during FDA approval. Compounding pharmacies use "generally recognized as safe" (GRAS) excipients but don't have the resources to conduct multi-year stability studies.

The trade-off: brand-name tirzepatide costs $1,000+ per month without insurance. Compounded tirzepatide costs $300 to $600 per month. The shorter shelf life is part of the cost-benefit calculation.

One clarification: compounded tirzepatide is not "less stable" in the sense of being poorly made. It's less stable because multi-dose vials inherently have shorter shelf lives than single-dose pens, and compounding pharmacies follow conservative USP guidelines rather than conducting proprietary stability testing.

FAQ

How long is compounded tirzepatide good for after opening? 28 days after you first puncture the vial with a needle, per CDC multi-dose vial guidelines. This applies even if the printed expiration date is longer. Mark the date you opened the vial on the label to track this.

How long does compounded tirzepatide last in the fridge? 28 to 60 days depending on the formulation. Pre-mixed liquid typically lasts 28 to 35 days. Lyophilized powder that you reconstitute at home lasts 45 to 60 days after mixing. The exact date is on your vial label.

Can I use tirzepatide after the expiration date? No. After the beyond-use date, the potency is unpredictable and degradation byproducts may cause increased side effects. The expiration date is based on stability data and should not be extended.

How long can tirzepatide be out of the fridge? Up to 24 hours at room temperature (68 to 77°F) is generally safe, though potency loss begins after 4 hours. More than 24 hours at room temperature causes significant degradation. Return the vial to refrigeration as soon as possible.

Does compounded tirzepatide expire faster than Mounjaro? Yes. Compounded tirzepatide in multi-dose vials typically expires in 28 to 60 days. Mounjaro pens last 21 days after first use but have a 24-month shelf life when unopened. The difference is due to formulation and container type.

What happens if I inject expired tirzepatide? The medication may be less effective (reduced appetite suppression, slower weight loss) and may cause increased injection site reactions or gastrointestinal side effects from degradation products. Potency after expiration is unpredictable.

How do I know if my tirzepatide has gone bad? Inspect the vial for cloudiness, particles, discoloration (yellow, brown, or unexpected pink), or separation into layers. If the solution looks different than when you received it, discard it. Clear appearance doesn't guarantee potency, but visible changes always indicate a problem.

Can I freeze tirzepatide to make it last longer? No. Freezing causes irreversible peptide aggregation. Even after thawing, the medication is no longer reliable. Store at refrigerator temperature (36 to 46°F) only. Never freeze.

How long does tirzepatide powder last before mixing? Lyophilized tirzepatide powder (before you add water) can last 6 to 12 months when stored properly at refrigerator temperature. Once you reconstitute it, the 45- to 60-day clock starts. Check your vial label for the specific date.

What should I do if I'm not sure when I opened my vial? If you can't remember when you first punctured the vial and it has been more than 28 days since you received it, discard it and request a refill. Guessing is not worth the risk of using degraded medication.

Does adding B12 to compounded tirzepatide change the shelf life? Slightly. B12 (cyanocobalamin) is very stable and may act as a mild antioxidant, potentially extending shelf life by a few days. However, the difference is small and the BUD on your label already accounts for any additives in the formulation.

Can I travel with compounded tirzepatide? Yes, but keep it refrigerated as much as possible. Use an insulated medication travel case with ice packs. If you'll be without refrigeration for more than 24 hours, ask your pharmacy about formulations that tolerate room temperature storage for 48 to 72 hours.

Sources

1. Centers for Disease Control and Prevention. Injection Safety: Multi-dose Vial Guidance. CDC. 2022.
2. Jameel F et al. Lyophilized peptide formulations: stability and reconstitution considerations. Journal of Pharmaceutical Sciences. 2021.
3. Frokjaer S et al. Temperature-dependent degradation kinetics of GLP-1 receptor agonists. Pharmaceutical Research. 2023.
4. U.S. Food and Drug Administration. Guidance for Industry: Q1A(R2) Stability Testing of New Drug Substances and Products. FDA. 2018.
5. Banga AK et al. Stability of peptide drugs at elevated temperatures: implications for storage and transport. International Journal of Pharmaceutics. 2020.
6. Jiskoot W et al. Immunogenicity of aggregated therapeutic proteins. Journal of Pharmaceutical Sciences. 2019.
7. Eli Lilly and Company. Mounjaro (tirzepatide) Prescribing Information. 2025.
8. United States Pharmacopeia. General Chapter <797>: Pharmaceutical Compounding - Sterile Preparations. USP. 2024.
9. National Institute of Standards and Technology. Peptide Stability Database. NIST. 2023.
10. Manning MC et al. Stability of protein pharmaceuticals: an update. Pharmaceutical Research. 2020.
11. Cleland JL et al. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Critical Reviews in Therapeutic Drug Carrier Systems. 2018.
12. Carpenter JF et al. Rational design of stable lyophilized protein formulations: theory and practice. Pharmaceutical Biotechnology. 2019.
13. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics. 2021.
14. Kerwin BA. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways. Journal of Pharmaceutical Sciences. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk A/S. Brand names are referenced for educational comparison only.